Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

M.D. Anderson Cancer Center · 2019
ClinicalTrials.gov · Datasets · License: Public Domain · 2019
Open Source ↗
cd19 positive, cd22 positive, minimal residual disease, progressive disease, recurrent b acute lymphoblastic leukemia, recurrent chronic lymphocytic leukemia, recurrent non-hodgkin lymphoma, refractory b acute lymphoblastic leukemia, refractory chronic lymphocytic leukemia, refractory non-hodgkin lymphoma, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 860629
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.